Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors

SAN DIEGO, Dec. 11, 2017 -- Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral tablet formulation.

This Phase 1, open-label, multi-center, dose-escalation study will evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered SM08502 in subjects with advanced solid tumors. Subjects will receive once-daily dosing of SM08502 for up to six 28-day cycles. The primary objectives of the study include safety and tolerability, incidence of dose limiting toxicities and certain PK measures. Secondary objectives include evaluating tumor response and Wnt pathway-related gene expression.

Gene mutations that over-activate the Wnt pathway have been demonstrated in a significant percentage of solid tumors. SM08502 is designed to inhibit this pathway which, when over-activated, can contribute to cancer cell proliferation and tumor growth. Previously-generated preclinical data demonstrated the ability of SM08502 to inhibit and reverse tumor growth in solid tumors, including colorectal, pancreatic, triple negative breast, liver, gastric, endometrial, ovarian and lung tumors.

“We are happy to start our Phase 1 trial for SM08502, which showed promising preclinical activity,” said Dr. Yusuf Yazici, Chief Medical Officer of Samumed. “SM08502 has the potential to provide significant clinical benefit to patients with a variety of advanced solid tumors and we look forward to the availability of top-line data from this Phase 1 study.”

About SM08502
SM08502 is a small molecule, Wnt pathway inhibitor being developed for the treatment of advanced solid tumors. SM08502’s mechanism-of-action has the potential to attenuate the expression of genes that control differentiation and proliferation of tumor cells.

About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Samumed’s clinical pipeline can be found here: https://www.samumed.com/pipeline/default.aspx

Corporate Contact:
Erich Horsley
Samumed, LLC
[email protected]
858-365-0200

Investor Contact:
Ashley Robinson
LifeSci Advisors
[email protected]
617-535-7742

Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
646-627-8384